Clinical trials: Postmenopausal Osteoporosis
Postmenopausal Osteopenia, Quality of Life
Translation and Cross -Cultural Validation of ECOS-16 Questionnaire in Urdu Language
Osteopenia is a clinical term to define the declined Bone Mineral Density (BMD) as per the normal reference values but not low enough to meet osteoporotic diagnostic criteria.
- Conditions
- Postmenopausal Osteopenia, Quality of Life, Validity, Reliability
- Trial name
- NCT04873960
- Where
- Pakistan
- Volunteers
- 80 people
- Sponsor
- Riphah International University
Osteoporosis
A Study of SB751689 in Japanese Postmenopausal Women
To investigate the safety and tolerability, PK and PD of SB751689 following single and 5-day multiple oral doses of 100, 200, and 400 mg in Japanese postmenopausal subjects.
- Trial name
- NCT00554255
- Testing
- SB751689
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis, Post-Menopausal
A Study of the Treatment of Postmenopausal Women With Osteoporosis
To compare the effect of treatment with teriparatide with that of salmon calcitonin in postmenopausal women with osteoporosis.
- Trial name
- NCT00543023
- Testing
- teriparatide 20 micrograms/day subcutaneous, salmon calcitonin 100 IU/day subcutaneous
- Where
- 2 sites in China
- Volunteers
- 104 people
- Sponsor
- Eli Lilly and Company
Osteoporosis, Postmenopausal
Effect of Laser Acupuncture on Forearm Bone Mineral Density and Wrist Pain in Osteoporotic Postmenopausal Women
Sixty-eight postmenopausal women diagnosed with osteoporosis aged between 50 and 60 years were randomly allocated to one of two equal sets. The drug treatment group received calcium and vitamin D3 supplement daily for 12 weeks.
- Trial name
- NCT05559619
- Testing
- Calcium carbonate, Vitamin D3, laser acupuncture therapy
- Where
- Egypt
- Volunteers
- 68 people
- Sponsor
- Cairo University
Osteoporosis
Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)
This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamic efficacy of MK0773 in healthy postmenopausal women.
- Trial name
- NCT01011725
- Testing
- MK 0773
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Osteoporotic Fractures, Osteoporosis, Postmenopausal
A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women
This proposed study was designed to investigate the prevalence of a 5-year incident osteoporotic fracture and evaluate the association of a 5-year change of 25-hydroxyvitamin D (25[OH]D)/bone turnover makers/bone mineral density…
- Trial name
- PK-VF (NCT02247011)
- Testing
- Questionaire survey, Bone mineral density examination, Vertebral fracture assessment
- Where
- China
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Postmenopausal Osteoporosis, Vertebral Fracture
How Vertebral Fractures Effect Balance In Postmenopausal Women
Osteoporosis is defined as low bone mineral density caused by altered bone microstructure, ultimately predisposing patients to fragility fractures.
- Conditions
- Postmenopausal Osteoporosis, Vertebral Fracture, Fracture of Vertebra, Fall
- Trial name
- NCT06502301
- Testing
- Cross-sectional study
- Where
- Turkey (Türkiye)
- Volunteers
- 95 people
- Sponsor
- Istanbul University - Cerrahpasa
Osteoporosis, Osteoporosis, Postmenopausal
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women.
- Trial name
- NCT07242612
- Testing
- Alendronate, Ibandronate; Risedronate, Teriparatide
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Khyber Medical University Peshawar
Postmenopausal Osteoporosis
Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk
A randomized, double-blind, two-group parallel, placebo-controlled clinical Phase III trial to compare the efficacy and safety of QL1206 and placebo in postmenopausal women with osteoporosis at high risk of fracture
- Trial name
- NCT04128163
- Testing
- QL1206
- Where
- China
- Volunteers
- 440 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Postmenopausal Osteoporosis
Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate
Patients who have received the appropriate number of years of alendronate or risedronate therapy will be recruited. Each patient will have received baseline BMD measurements performed at the spine and the hip by DXA.
- Trial name
- NCT00778154
- Where
- 8 sites in United States, Canada
- Volunteers
- 105 people
- Sponsor
- Warner Chilcott
Endometrial Hyperplasia, Osteoporosis
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00675688
- Testing
- Bazedoxifene/Conjugate Estrogens (CE), Raloxifene
- Volunteers
- 3,544 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Postmenopausal Osteoporosis
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
The aim of the study is to assess the relative antiresorptive properties of 2 osteoporosis medications when combined with teriparatide.
- Trial name
- NCT01750086
- Testing
- Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Postmenopausal Osteoporosis
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women
This study is designed to provide information about the bone anabolic properties and absorption profile of Unigene's PTH Analog when administered as oral tablets over a period of 24 weeks to postmenopausal women with osteoporosis.
- Trial name
- NCT01321723
- Testing
- PTH analog, Forsteo (Teriparatide)
- Where
- 4 sites in Denmark, Estonia
- Volunteers
- 97 people
- Sponsor
- Unigene Laboratories Inc.
Postmenopausal Women With Primary Osteoporosis
STEP: Study of Imaging Techniques (ImaTx and DXA) in Postmenopausal Women With OstEoporosis Using Preotact (FP-008-ES)
The primary objective of the study is to explore the relationship between a new image technology (ImaTx), that analyzes the trabecular structure of the bone using digitized radiographs and the bone mineral density (BMD) measured…
- Trial name
- NCT00583518
- Testing
- Parathyroid hormone (PTH)
- Where
- Denmark
- Volunteers
- 129 people
- Sponsor
- Nycomed
Osteoarthritis
Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin
Relacatib is being developed for the treatment of osteoporosis, osteoarthritis and possibly other bone disorders. Recent results suggest that relacatib interacts with the way our bodies metabolise drugs and so some drugs which…
- Trial name
- NCT00411190
- Testing
- Relacatib, Acetaminophen, Ibuprofen
- Where
- 2 sites in Belgium
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Osteoporosis
The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton
There are over 10 million individuals with asthma using inhaled glucocorticoids (IGCs) in the United States. While oral GCs are recognized to have destructive skeletal effects, far less is known about the effects of IGCs.
- Trial name
- NCT02357277
- Testing
- Budesonide
- Volunteers
- healthy volunteers welcome
- Sponsor
- Columbia University
Osteoporosis Risk
Evaluation of the Effects of Bicarbonate-calcium Water in Premenopausal and Postmenopausal Women as a Prevention of Osteoporosis
The goal of this clinical trial is to evaluate the effect of bicarbonate-calcium water for the prevention of osteoporosis. Participants are women in pre- or post- menopausal state.
- Trial name
- NCT05854342
- Testing
- bicarbonate-calcium water
- Where
- Italy
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Salerno
Postmenopausal Osteoporosis
Alendronate in an Weekly Effervescent Tablet Formulation Following Denosumab Discontinuation
Discontinuation of denosumab results in a rebound response of bone turnover markers, which rise above baseline at 3 months and remain elevated until reaching again baseline levels approximately 30 months after the last dose.
- Trial name
- BAD (NCT04338529)
- Testing
- Binosto 70Mg Effervescent Tablet
- Where
- Greece
- Volunteers
- 92 people
- Sponsor
- 251 Hellenic Air Force & VA General Hospital
Postmenopausal Women With Osteoporosis
To Evaluate the Efficacy and Safety of Abaloparatide Injection (QLG2128) in the Treatment of Postmenopausal Women With Osteoporosis and at High Risk of Fracture
The purpose of this study is to evaluate the efficacy and safety of QLG2128 in the treatment of postmenopausal women with osteoporosis and at high risk of fracture.
- Trial name
- NCT06898060
- Testing
- QLG2128, Teriparatide Injection
- Volunteers
- 282 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Osteoporosis, Postmenopausal, Osteopenia
Validation, Reliability and Pilot Test of the Personalized Exercise Questionnaire (PEQ)
The PEQ is the first tool to measure facilitators, barriers, and preferences to exercise in people with osteoporosis.
- Trial name
- NCT03125590
- Testing
- Testing the PEQ (Personalized Exercise Questionnaire)
- Where
- Canada
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- McMaster University